SCHEMBL6320132

SCHEMBL6320132

CNC(=O)[C@@H](Cc1ccc(OC)cc1)N(C)C(=O)[C@@H](Cc1csc2ccccc12)N(C)C(=O)C=CCC(C)(C)N

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 8/20 0.46
KLKB1 P03952 2/20 0.37
KLK1 P06870 1/20 0.37
OPRM1 P35372 2/20 0.36
OPRD1 P41143 2/20 0.36
OPRK1 P41145 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320121 1.00 GHSR (0.46) GHSRKLKB1KLK1OPRM1OPRD1
SCHEMBL6319016 0.92 GHSR (0.49) GHSROPRM1OPRD1OPRK1
SCHEMBL6319014 0.92 GHSR (0.49) GHSROPRM1OPRD1OPRK1
SCHEMBL6318192 0.89 GHSR (0.52) GHSR
SCHEMBL6318187 0.89 GHSR (0.52) GHSR
SCHEMBL6326553 0.89 GHSR (0.52) GHSR
SCHEMBL6326556 0.89 GHSR (0.52) GHSR
SCHEMBL6319852 0.89 GHSR (0.49) GHSR
SCHEMBL6319845 0.89 GHSR (0.49) GHSR
SCHEMBL6316698 0.89 GHSR (0.49) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 GHSR 2/4885KLKB1 988/4885KLK1 802/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR GHSR 2/4885KLKB1 1152/4885KLK1 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.